Question explored with the scientific record
Does hrt cause bleeding after sex in menopause
The short version: HRT can cause postcoital bleeding, but the evidence is thin on how often and by which exact mechanism.
The evidence you retrieved does not directly study postcoital bleeding in women on HRT. It studies endometrial thickness, polyps, and unscheduled bleeding in general [2, 4, 5, 8, 11, 14]. The closest study, a 2025 retrospective analysis of 235 women on transdermal estradiol plus progesterone, found no endometrial hyperplasia or cancer in those with unscheduled bleeding, but 78% of a separate small cohort on estradiol/testosterone implants who had a thickened endometrium had polyps, and one polyp contained cancer [2, 14]. Polyps are fragile and can bleed with friction from sex. A 2004 study found that an endometrial thickness over 4.5 mm on HRT was linked to polyps and hyperplasia in women with abnormal bleeding [11]. The mechanism is plausible: estrogen stimulates the endometrium, and without enough progesterone to oppose it, the lining can grow irregularly, forming polyps or hyperplasia that bleed when disturbed [2, 3, 4]. But the evidence is all retrospective or observational, not a controlled trial comparing bleeding rates in HRT users versus non-users. No study in this set measured how many women actually had bleeding after sex specifically.
| Finding | Source |
|---|---|
| Polyps found in 78% of implant users with thick endometrium | [14] |
| No endometrial cancer in 235 transdermal HRT users with unscheduled bleeding | [2] |
| Endometrial thickness >4.5 mm linked to polyps and hyperplasia on HRT | [11] |
| One polyp-associated cancer in 23 implant users | [14] |
My call: HRT can cause postcoital bleeding, most likely through endometrial polyps or hyperplasia, but the absolute risk is not well quantified in the evidence you provided. Confidence: low — the studies are small, retrospective, and do not directly answer the question.
Sources examined 24
-
Orally Administered Combination of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin in the Prevention of Postcoital Recurrent Urinary Tract Infections: Analysis of 98 Women in Reproductive Age After 6 Months of Treatment
This retrospective study assessed the efficacy and safety of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin, and quercetin for preventing postcoital recurrent UTIs in 98 reproductive-age women over 6 months, finding reduced UTI recurrences a…
DOI: 10.1097/SPV.0000000000000560 -
Endometrial thickness and pathology in postmenopausal women with bleeding on transdermal 17β-estradiol plus body-identical progesterone
Retrospective analysis of 235 postmenopausal women with unscheduled bleeding on transdermal 17β-estradiol plus micronised progesterone found no convincing link between endometrial thickness and transdermal estradiol dose or progesterone dose, with a low prevalence of endometrial…
DOI: 10.1007/s00404-025-08161-w -
Levonorgestrel intrauterine system for endometrial protection
This review discusses the efficacy and safety of the levonorgestrel intrauterine system as a progestogen component in hormone replacement therapy for endometrial protection in menopausal women, highlighting its potential to reduce endometrial thickness and avoid hyperplasia.
DOI: 10.1258/136218006775992176 -
Bleeding Pattern and Endometrial Changes During Continuous Combined Hormone Replacement Therapy
This study investigates the effects of three different doses of medroxyprogesterone acetate combined with a fixed dose of estrone sulfate on bleeding patterns and endometrial changes in postmenopausal women over a two-year period, finding that all doses provided adequate endomet…
DOI: 10.1097/00006250-199805000-00007 -
Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol
This study evaluates the efficacy and safety of a low-dose hormone therapy regimen combining transdermal estradiol and vaginal micronized progesterone in postmenopausal women, highlighting its potential to minimize endometrial hyperplasia while addressing menopausal symptoms.
DOI: 10.3109/13697137.2011.644360 -
The risk of premalignant and malignant pathology in endometrial polyps
A prospective cohort study of 248 women undergoing outpatient hysteroscopy to assess the malignant potential of endometrial polyps by comparing polyp and non-polyp tissues, finding higher rates of hyperplasia but no difference in cancer risk, supporting polyp removal in symptoma…
DOI: 10.1034/j.1600-0412.2000.079004317.x -
The malignant potential of endometrial polyps
A retrospective study of 430 hysteroscopic endometrial polyps quantified the malignant/premalignant potential, found postmenopausal status and polyp size >1.5 cm as significant risk factors, demonstrated that many polyps are asymptomatic yet harbor premalignant/malignant changes…
DOI: 10.1016/j.ejogrb.2004.02.002 -
Evaluation of postmenopausal endometrium
A critical editorial review of how transvaginal ultrasound and saline infusion sonohysterography (SIS) are used to evaluate the postmenopausal endometrium, arguing that ultrasound provides valuable noninvasive information and can guide sampling but cannot replace endometrial bio…
DOI: 10.1046/j.1469-0705.1998.12050295.x -
Total laparoscopic hysterectomy
This study correlates transvaginal ultrasound endometrial assessment with histologic and hysteroscopic findings in 910 asymptomatic postmenopausal women, identifying significant findings related to endometrial thickness and its implications for further diagnostic procedures.
DOI: 10.1016/s1074-3804(96)80169-1 -
Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen
This study evaluates the endometrial safety and tolerability of a triphasic sequential hormone replacement therapy regimen using estradiol valerate and medroxyprogesterone acetate in postmenopausal women.
DOI: 10.1080/13697130310001651445 -
Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study
This prospective multicenter study evaluates the role of endometrial thickness as a predictor of endometrial abnormalities in postmenopausal women undergoing hormone therapy, finding that a thickness greater than 4.5 mm is significantly associated with histological abnormalities.
DOI: 10.1016/j.fertnstert.2003.10.043 -
Expression of Estrogen and Progesterone Receptor In Perimenopausal and Postmenopausal Endometrium.
Estrogen and progesterone receptor expression in endometrium from perimenopausal and postmenopausal bleeding is high in non-malignant tissues, declines in malignant/malignant-adjacent lesions, and remains higher in perimenopausal samples, supporting receptor status as a potentia…
DOI: 10.64149/j.carcinog.24.3s.547-555 -
The Diagnostic Value of Power Doppler Measurements in the Endometrium of Women with Postmenopausal Bleeding
In women with postmenopausal bleeding, power Doppler measurements of endometrial vessels were evaluated for diagnostic accuracy; while PI < 1 improves sensitivity and specificity, power Doppler cannot replace invasive biopsy, and combining TVS endometrial thickness with power Do…
DOI: 10.1006/gyno.2000.5766 -
Hysteroscopic findings in postmenopausal patients with a thick endometrium after using implants of oestradiol and testosterone
Endometrial polyps are the most frequent intrauterine pathology in postmenopausal patients with increased endometrial thickness after implants of oestradiol and testosterone, with one polyp containing endometrial carcinoma.
DOI: 10.1046/j.1365-2508.2000.00362.x -
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women
This study evaluates the efficacy and safety of synthetic conjugated estrogens B (SCE-B) in treating vulvovaginal atrophy in symptomatic postmenopausal women through a randomized, double-blind, placebo-controlled trial.
DOI: 10.1016/j.fertnstert.2007.07.1359 -
Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Conjugated Estrogen Cream in Postmenopausal Women with Vulvovaginal Atrophy: A Randomized Clinical Trial
This randomized clinical trial in Iran compared fractional CO2 laser treatment to vaginal conjugated estrogen cream in 130 postmenopausal women with vulvovaginal atrophy, finding laser treatment produced greater improvements in vulvovaginal symptoms, sexual satisfaction, and sex…
DOI: 10.5539/jmbr.v9n1p67 -
Re: Cystoscopic Injections of Dextranomer Hyaluronic Acid Into Proximal Urethra for Urethral Incompetence: Efficacy and Adverse Outcomes
This is an editorial commentary on vulvovaginal atrophy (VVA) that outlines its clinical features, the use of vaginal estrogen therapies in postmenopausal women, and safety considerations—particularly for breast cancer survivors—while noting that systemic absorption is limited a…
DOI: 10.1016/s0022-5347(11)60274-7 -
Vulvovaginal Atrophy
This concise review discusses vulvovaginal atrophy (VVA), its prevalence, symptoms, physiological mechanisms, clinical findings, diagnostic tests, treatment options, and the implications for postmenopausal women, particularly those with a history of breast cancer.
DOI: 10.4065/mcp.2009.0413 -
Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?
This review examines the safety and efficacy of local hormone therapy for managing genitourinary syndrome of menopause (GSM) in breast cancer patients, highlighting the potential benefits and risks associated with estrogen treatments.
DOI: 10.1080/09513590.2017.1290076 -
Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women
A partly randomized, open-label, multiple-rising-dose study in 49 postmenopausal women found estetrol (2–40 mg/day) to be generally safe and capable of improving vaginal cytology and vasomotor symptoms, with endometrial proliferation observed only at the 10 mg dose necessitating…
DOI: 10.1016/j.maturitas.2016.06.017 -
Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels
This study reviews the effects of vaginal administration of estradiol on plasma estradiol levels, highlighting the differences in absorption based on dose, preparation, and timing, and concludes that low-dose vaginal estrogen is effective for managing vulvovaginal atrophy with m…
DOI: 10.3109/13697137.2014.947254 -
Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA
This study investigates the serum levels of DHEA and its metabolites in postmenopausal women with vulvovaginal atrophy after 52 weeks of daily intravaginal administration of 0.50% DHEA, confirming that systemic estrogen exposure remains within normal postmenopausal values.
DOI: 10.1515/hmbci-2015-0035 -
Science of intracrinology in postmenopausal women
This study explores the mechanisms of intracrinology in postmenopausal women, highlighting how dehydroepiandrosterone (DHEA) serves as a local source of sex steroids, effectively treating vulvovaginal atrophy without significant systemic exposure or safety concerns.
DOI: 10.1097/GME.0000000000000808 -
Ospemifene in the Treatment of Vulvovaginal Atrophy
This article reviews the efficacy and safety of ospemifene for postmenopausal vulvar and vaginal atrophy (VVA)/dyspareunia, summarizing two pivotal 12-week randomized trials and a longer 52-week trial, showing improvements in vaginal epithelium, pH, dryness, and dyspareunia with…
DOI: 10.1177/1060028014526036